期刊文献+

小剂量尿酸氧化酶治疗急性脑梗死的临床效果 被引量:2

EFFECTS OF SMALL DOSE UROKINASE ON ACUTE CEREBRAL INFARCTION
下载PDF
导出
摘要 ①目的 探讨小剂量尿酸氧化酶治疗急性脑梗死的效果。②方法 将 10 6例急性脑梗死病人随机分为治疗组 5 6例 ,对照组 5 0例。对照组应用脱水剂、活血化淤、脑保护剂及抗凝剂等治疗。治疗组在对照组的基础上加用小剂量尿酸氧化酶治疗。③结果 在治疗后 2 4h ,治疗组与对照组的临床评分差异无显著性 (F =2 .17,P >0 .0 5 )。治疗后 7d ,30d临床评分 ,两组差异有显著性 (F =4 .6 6 ,q =12 .11,9.87,P <0 .0 5 ;F =6 .2 3,q =17.83,11.91,P <0 .0 5 ) ;6h以内与 7~ 2 4h溶栓治疗在 7d ,30d的临床评分也有显著性差异 (q=7.2 9,8.16 ,P <0 .0 5 )。④结论 小剂量尿酸氧化酶治疗急性脑梗死在临床上有一定的疗效 ,并且安全、方便。溶栓时间越早效果越好。 Objective\ To study the effects of urokinase on acute cerebral infarction . \ Methods\ 106 patients with acute cerebral infarction were randomly divided into Treated Group (56 cases ,regular therapy plus urokinase) and Control Group (50 cases , regular therapy ) .\ Results\ 24 hours after the treatment, the differences of clinical score between the two groups were not significant ( F=2.17, P >0.05) . The results showed that the difference of clinical score was significant after 7 and 30 day treatment of the two groups ( F=4.66, q=2.11, 9.87, P<0.05; F=6.23, q=17.83, 11.91, P <0.05) . The clinical score of thrombolytic therapy 7 and 30 days after the treatment showed significant difference for the patients treated within 6 hours as compared with those within 7-24 hours of the onset( q=7.29, 8.16, P <0.05). \ Conclusion\ Small dose of urokinase is effective, safe and simple clinically for acute cerebral infarction . The sooner use of urokinase, the better effect will be .
出处 《齐鲁医学杂志》 2002年第1期39-40,共2页 Medical Journal of Qilu
关键词 脑梗死 尿酸氧化酶 血栓溶解 cerebral infarction urokinase thrombolytic therapy
  • 相关文献

参考文献3

二级参考文献3

  • 1Li Y,J Neurol Sci,1995年,128卷,134页
  • 2Zhang R L,Neurology,1994年,44卷,1747页
  • 3Chen H,J Neurol Sci,1993年,118卷,109页

共引文献90

同被引文献46

  • 1毕桂南.急性缺血性脑卒中治疗研究的新进展[J].国外医学(神经病学.神经外科学分册),1995,22(5):244-246. 被引量:16
  • 2Gille H, Kowalski J, Li B, et 8.1. Analysis of biological effects and signaling properties of Fit - 1 ( VEGFR - 1 ) and KDR( VEGFR - 2 )[J]. J Biol Chem ,2001,276:3222 - 3230.
  • 3Dumont DJ, Jussila L, Taipale J, et 81. Cardiovascular failure in mouse embryos deficient in VEGF Receptor-3 [J]. Science,1998,282:946 - 949.
  • 4Ferrajoli A ,Manshouri T,Estrov Z,et a]. High levels of vasodar endothelial growth factor receptor -2 cone]ate with shortened survival inchnmic lymphocytic leukemia[ J]. Clin Cancer Res ,2001,7:795 - 799.
  • 5Dankbar B,Padro T,Le R,et al. Vascular endothelial growth factor and interleukin - 6 in paracrine tumor - stromal cell interactions in multiple myeloma[J]. Blood,2000,95:2630 -2636.
  • 6Roeckl W,Hecht D,Sztajer H ,et al. Differet,tial binding characteristics and cellular inhibition by soluble forms of KDR and FLT - 1[J]. Exp Cell Res ,1998 ,241:161 -170.
  • 7Neufeld G, Cohen T. Vascular endothelial growth factor(VEGF) and its receptors[ J]. FASEB J,1999,13:9 -22.
  • 8Vincenti V, Cassano C, Rocchi M, et 81. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3 [ J ].Circulation, 1996,93 : 1493 - 1495.
  • 9Grimmond S, Lagererantz J, Drinkwater C, et 81. Cloning and characterization of a novel human gene related to vascular endothelial growth factor[ J]. Genome Res, 1996,6 : 124 - 131.
  • 10Paavonen K, Horelli -Kuitunen N, Chilov D, et 81. Novel human vasculax endothelial growth factor genes VEGF - B and VEGF - C localize to chromosomes 11 q13 and 4 q34, respectively [ J]. Circulation, 1996,93:1079 - 1082.

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部